Orchestra BioMed Holdings, Inc. (OBIO)
NASDAQ: OBIO · Real-Time Price · USD
5.77
+0.33 (6.07%)
Nov 22, 2024, 4:00 PM EST - Market closed

Company Description

Orchestra BioMed Holdings, Inc. operates as a biomedical innovation company.

The company’s flagship product candidates include BackBeat Cardiac Neuromodulation Therapy (CNT) for the treatment of hypertension (HTN); and Virtue Sirolimus AngioInfusion Balloon (SAB) for the treatment of atherosclerotic artery disease.

Its products also comprise FreeHold devices and minimally invasive surgery devices. The company has a collaboration agreement with Medtronic, Inc. for the development and commercialization of BackBeat CNT for the treatment of HTN in patients indicated for a cardiac pacemaker; and a strategic collaboration with Terumo Medical Corporation for the development and commercialization of Virtue SAB for the treatment of coronary and peripheral artery disease.

Orchestra BioMed Holdings, Inc. is based in New Hope, Pennsylvania.

Orchestra BioMed Holdings, Inc.
Orchestra BioMed Holdings logo
Country United States
Founded 2017
Industry Biotechnology
Sector Healthcare
Employees 56
CEO David Hochman

Contact Details

Address:
150 Union Square Drive
New Hope, Pennsylvania 18938
United States
Phone 212 862 5797
Website orchestrabiomed.com

Stock Details

Ticker Symbol OBIO
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001814114
CUSIP Number 68572M106
ISIN Number US68572M1062
SIC Code 3841

Key Executives

Name Position
David P. Hochman Founder, Chairman of the Board of Directors and Chief Executive Officer
Darren R. Sherman Founder, President, Chief Operating Officer and Director
Andrew Lawrence Taylor M.B.A. Chief Financial Officer
William Reed Little Executive Vice President of Corporate Development and Strategy
Dr. Yuval Hay Mika D.Sc, Ph.D. GM and Chief Technology Officer of Bioelectronic Therapies
Dr. George Papandreou Ph.D. GM and Senior Vice President of Focal Therapies
Dr. Hans-Peter Stoll M.D., Ph.D. Chief Clinical Officer
Dr. Avraham Matityahu Fischer M.D. Senior Vice President of Medical Affairs and Innovation
Bob Laughner Senior Vice President of Regulatory and Quality
Juan Lorenzo Senior Vice President of Product Development

Latest SEC Filings

Date Type Title
Nov 12, 2024 10-Q Quarterly Report
Nov 8, 2024 SC 13G Statement of acquisition of beneficial ownership by individuals
Oct 23, 2024 SC 13G Statement of acquisition of beneficial ownership by individuals
Sep 10, 2024 144 Filing
Sep 10, 2024 144 Filing
Sep 9, 2024 144 Filing
Sep 9, 2024 144 Filing
Sep 6, 2024 144 Filing
Sep 6, 2024 144 Filing
Sep 5, 2024 144 Filing